Christopher M Heaphy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9223023/publications.pdf

Version: 2024-02-01

97 papers 5,267 citations

33 h-index 91884 69 g-index

106 all docs 106 docs citations

106 times ranked 8341 citing authors

#	Article	IF	CITATIONS
1	Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations. Science, 2011, 333, 425-425.	12.6	891
2	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
3	Tracking the clonal origin of lethal prostate cancer. Journal of Clinical Investigation, 2013, 123, 4918-4922.	8.2	440
4	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.8	423
5	Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Modern Pathology, 2012, 25, 1033-1039.	5.5	155
6	Mutation of a single allele of the cancer susceptibility gene <i>BRCA1</i> leads to genomic instability in human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17773-17778.	7.1	134
7	Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature Medicine, 2019, 25, 1260-1265.	30.7	120
8	Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Research and Treatment, 2009, 118, 229-239.	2.5	114
9	Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clinical Cancer Research, 2017, 23, 1598-1606.	7.0	101
10	Telomeres: Prognostic markers for solid tumors. International Journal of Cancer, 2006, 119, 2255-2260.	5.1	97
11	Telomere Length and Pulse Pressure in Newly Diagnosed, Antipsychotic-Naive Patients With Nonaffective Psychosis. Schizophrenia Bulletin, 2009, 35, 437-442.	4.3	92
12	Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. Cancer Discovery, 2013, 3, 1130-1141.	9.4	77
13	Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. International Journal of Cancer, 2011, 129, 1310-1321.	5.1	74
14	ASSOCIATION BETWEEN CANCER-FREE SURVIVAL AND TELOMERE DNA CONTENT IN PROSTATE TUMORS. Journal of Urology, 2005, 173, 610-614.	0.4	73
15	Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in Highâ€Grade Astrocytomas. Brain Pathology, 2013, 23, 237-243.	4.1	73
16	Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. British Journal of Cancer, 2015, 112, 769-776.	6.4	73
17	Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. International Journal of Cancer, 2006, 119, 108-116.	5.1	72
18	Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naÃ-ve patients with depression. Brain, Behavior, and Immunity, 2013, 28, 49-53.	4.1	71

#	Article	IF	Citations
19	Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Research and Treatment, 2006, 99, 193-202.	2.5	64
20	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Annals of Surgery, 2020, 271, 566-573.	4.2	64
21	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20482-20488.	7.1	63
22	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, 2022, 71, 961-973.	12.1	60
23	Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Modern Pathology, 2013, 26, 1586-1593.	5. 5	56
24	Alternative lengthening of telomeres, ATRX loss and H3â€K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathology, 2019, 29, 126-140.	4.1	54
25	Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> Immunohistochemistry, and <i>In Situ</i> Immunohistochemistry, and <i>In Situ</i> Immunohistochemistry, and <i>Immunohistochemistry, and <i>Immunohistochemistry, and <i <i="" and="" immuno<="" immunohistochemistry,="" td=""><td>7.0</td><td>52</td></i></i></i>	7.0	52
26	MYC drives overexpression of telomerase RNA ($\langle i \rangle hTR \langle i \rangle /\langle i \rangle TERC \langle i \rangle$) in prostate cancer. Journal of Pathology, 2018, 244, 11-24.	4.5	51
27	ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS ONE, 2018, 13, e0204159.	2.5	48
28	Mannose Receptor–positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. European Urology Oncology, 2019, 2, 429-436.	5 . 4	46
29	The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Modern Pathology, 2009, 22, 1423-1431.	5 . 5	45
30	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9690-9699.	3.4	45
31	The potential utility of telomereâ€related markers for cancer diagnosis. Journal of Cellular and Molecular Medicine, 2011, 15, 1227-1238.	3.6	43
32	Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathology, 2017, 125, 544-551.	2.4	41
33	Telomere DNA Content Predicts Breast Cancer–Free Survival Interval. Clinical Cancer Research, 2007, 13, 7037-7043.	7.0	37
34	Visualization of Telomere Integrity and Function In Vitro and In Vivo Using Immunofluorescence Techniques. Current Protocols in Cytometry, 2015, 73, 12.40.1-12.40.31.	3.7	37
35	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Modern Pathology, 2011, 24, 256-266.	5.5	34
36	Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases. Journal of the American College of Surgeons, 2014, 218, 628-635.	0.5	34

#	Article	IF	Citations
37	Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology, 2014, 386, 101-120.	3.2	32
38	Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocrine Pathology, 2020, 31, 108-118.	9.0	32
39	Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Human Pathology, 2016, 56, 93-100.	2.0	31
40	Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2015, 75, 1160-1166.	2.3	29
41	Telomere length as a risk factor for hereditary prostate cancer. Prostate, 2014, 74, 359-364.	2.3	27
42	Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. Modern Pathology, 2011, 24, 194-200.	5.5	25
43	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030403.	6.2	25
44	Functional Loss of <i>ATRX</i> and <i>TERC</i> Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells. Molecular Cancer Research, 2019, 17, 2480-2491.	3.4	25
45	Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Modern Pathology, 2018, 31, 1787-1800.	5.5	24
46	Chemiluminescent Measurement of Telomere DNA Content in Biopsies. BioTechniques, 2002, 33, 144-148.	1.8	23
47	Protease nexin-1 expression is altered in human breast cancer. Cancer Cell International, 2006, 6, 16.	4.1	23
48	Organâ€wide telomeric status in diseased and diseaseâ€free prostatic tissues. Prostate, 2010, 70, 1471-1479.	2.3	23
49	Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas. Acta Neuropathologica, 2016, 132, 761-763.	7.7	23
50	Telomere DNA Content in Prostate Biopsies Predicts Early Rise in Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer. Urology, 2010, 75, 724-729.	1.0	20
51	Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fineâ€needle aspiration. Diagnostic Cytopathology, 2020, 48, 308-315.	1.0	20
52	Telomere Length Is Related to Alternative Splice Patterns of Telomerase in Thyroid Tumors. American Journal of Pathology, 2011, 179, 1415-1424.	3.8	19
53	Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
54	Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Research and Treatment, 2009, 117, 17-24.	2.5	16

#	Article	IF	Citations
55	High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 668-675.	2.5	16
56	Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology, 2022, 129, 679-693.	5.2	16
57	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. American Journal of Surgical Pathology, 2019, 43, 1083-1091.	3.7	15
58	Coordinate regulation between expression levels of telomereâ€binding proteins and telomere length in breast carcinomas. Cancer Medicine, 2012, 1, 165-175.	2.8	14
59	Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cellular Oncology (Dordrecht), 2020, 43, 847-861.	4.4	14
60	Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. Pathology, 2020, 52, 336-347.	0.6	14
61	Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Modern Pathology, 2020, 33, 1475-1481.	5.5	13
62	Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. Journal of Pathology, 2021, 253, 415-426.	4.5	13
63	A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. Molecular and Cellular Biochemistry, 2007, 297, 179-187.	3.1	12
64	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	5.2	12
65	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prevention Research, 2015, 8, 737-742.	1.5	11
66	Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer?. Prostate Cancer, 2016, 2016, 1-8.	0.6	11
67	Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 649-653.	2.8	11
68	Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 676-680.	2.5	11
69	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. Endocrine-Related Cancer, 2020, 27, T9-T25.	3.1	10
70	Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. Cancers, 2022, 14, 3015.	3.7	10
71	A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica, 2013, 126, 607-608.	7.7	9
72	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget, 2015, 6, 25240-25251.	1.8	9

#	Article	IF	Citations
73	Clinical implications of cellâ€ofâ€origin epigenetic characteristics in nonâ€functional pancreatic neuroendocrine tumors. Journal of Pathology, 2022, 256, 143-148.	4.5	9
74	High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. Human Pathology, 2016, 54, 106-112.	2.0	8
75	SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Modern Pathology, 2021, 34, 1810-1819.	5.5	8
76	Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate, 2022, 82, 1005-1015.	2.3	8
77	Telomere length alterations unique to invasive lobular carcinoma. Human Pathology, 2015, 46, 1197-1203.	2.0	7
78	Cocaine use may induce telomere shortening in individuals with HIV infection. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 11-17.	4.8	7
79	ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation. Journal of Neuropathology and Experimental Neurology, 2019, 78, 703-708.	1.7	7
80	Assessment of the Frequency of Allelic Imbalance in Human Tissue Using a Multiplex Polymerase Chain Reaction System. Journal of Molecular Diagnostics, 2007, 9, 266-271.	2.8	6
81	Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry, 2019, 65, 189-198.	3.2	6
82	Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver International, 2021, 41, 2499-2510.	3.9	6
83	The prostate tissueâ€based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. Journal of Pathology: Clinical Research, 2022, 8, 481-491.	3.0	6
84	Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate, 2018, 78, 233-238.	2.3	5
85	A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease. Brain Pathology, 2019, 29, 45-52.	4.1	5
86	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	2.0	5
87	Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. BMC Cancer, 2015, 15, 823.	2.6	3
88	Genetic alterations associated with ALTered telomeres. Oncotarget, 2018, 9, 33739-33740.	1.8	3
89	Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations. Cancer Causes and Control, 2018, 29, 759-767.	1.8	3
90	Surviving Telomere Attrition with the MiDAS Touch. Trends in Genetics, 2019, 35, 783-785.	6.7	3

#	Article	IF	CITATIONS
91	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Laboratory Investigation, 2020, 100, 1003-1013.	3.7	3
92	Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. Cancer Prevention Research, 2021, 14, 463-470.	1.5	3
93	Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathology, 2021, 129, 841-843.	2.4	2
94	Comprehensive assessment of <i>ATRX</i> mutation, protein expression, and alternative lengthening of telomeres (ALT) phenotype in grade II and III gliomas Journal of Clinical Oncology, 2017, 35, 2064-2064.	1.6	2
95	Diagnostic significance of allelic imbalance in cancer. Expert Opinion on Medical Diagnostics, 2007, 1, 159-168.	1.6	1
96	NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST. Neuro-Oncology, 2020, 22, iii417-iii418.	1.2	0
97	Investigating the Molecular and Phenotypic Differences in Pancreatic Neuroendocrine Tumor (PanNET) Cells with Functional Loss of Either <i>ATRX</i>	0.5	0